文献速递鼻科

生物制剂在慢性鼻窦炎中的作用:系统综述

The role of biologics in chronic rhinosinusitis: a systematic review.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-12-23

该系统综述检索数据库后纳入6项随机对照试验,评估单克隆抗体治疗慢性鼻窦炎伴鼻息肉(CRSwNP)和不伴鼻息肉(CRSsNP)的作用。结果显示奥马珠单抗和美泊利单抗改善CRSwNP患者的内镜鼻息肉评分(EPS)和症状评分,瑞利珠单抗缩小鼻内IL-5升高患者的鼻息肉,度普利尤单抗使EPS降低70%而安慰剂组为20%(p<0.001)。未报告CRSsNP或手术联合生物制剂的研究。

要点

  • 奥马珠单抗和美泊利单抗可改善CRSwNP患者EPS和症状评分。
  • 度普利尤单抗使EPS降低70%,安慰剂组20%(p<0.001)。
  • 瑞利珠单抗可缩小鼻内IL-5升高患者的鼻息肉。

核心结论

  • 证据表明单克隆抗体可使CRSwNP患者获得临床改善。
  • 仍需进一步研究确定长期效果、与其他药物治疗的可比性及潜在副作用。

研究设计与样本

  • 系统综述,综合数据库检索后识别5341项相关研究。
  • 6项研究符合纳入标准,均为随机对照试验。

主要发现

  • 与安慰剂相比,奥马珠单抗和美泊利单抗改善CRSwNP患者的EPS和症状评分。
  • 瑞利珠单抗缩小鼻内IL-5水平升高患者的鼻息肉大小。
  • 度普利尤单抗治疗使EPS降低70%,安慰剂组为20%(p<0.001)。
  • 这些单克隆抗体靶向CRSwNP病理生理中不同的炎症标志物。
  • 无研究报告CRSsNP或手术联合生物制剂;未报告严重不良事件。

关键数值与推荐

  • 度普利尤单抗使EPS降低70%,安慰剂组为20%(p<0.001)。

临床怎么用

  • 单克隆抗体可用于改善CRSwNP的临床结局。
  • 需权衡长期效果、与其他药物治疗的可比性及潜在副作用。

局限性

  • 缺乏CRSsNP及手术联合生物制剂的研究数据。
  • 长期效果、与其他药物治疗的可比性及潜在副作用尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis (CRS) refractory to medical and surgical treatment is challenging. It impacts patients' quality of life significantly. The pathophysiology of CRS has some similarities to allergic asthma and allergic rhinitis (AR) and includes eosinophilia, T-helper cell 2 cytokines, and local immunoglobilin E formation. Monoclonal antibody therapy has been used successfully in asthma and AR and more recently in CRS. Our was aim to systematically review the literature and identify the role of monoclonal antibodies (MAbs) in the treatment of CRS with polyps (CRSwNP) and without polyps (CRSsNP), especially with regard to comparability with current medical treatment, efficacy, and risk of complications. In addition, the role of surgery and biologics was evaluated. METHODS: We identified at total of 5341 relevant studies after a comprehensive database search. Six studies met the inclusion criteria, all 6 randomized, controlled trials. RESULTS: Treatment with omalizumab and mepolizumab demonstrated improvements in endoscopic nasal polyp score (EPS) and symptoms score in patients with CRSwNP when compared with placebo. Reslizumab reduced nasal polyp size in patients with raised intranasal interleukin-5 levels. Dupilumab treatment resulted in a 70% reduction in EPS compared with 20% in the placebo group (p < 0.001). These MAbs target different inflammatory markers involved in the pathophysiology of CRSwNP. None of the studies reported on CRSsNP or combined surgery with biologics. No severe adverse events were reported. CONCLUSION: Evidence demonstrates that use of MAbs leads to clinical improvement in CRSwNP. However, further research is required to determine their long-term effects, comparability to other medical treatments, and potential side effects.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Iqbal IZ, Kao SS, Ooi EH, et al. The role of biologics in chronic rhinosinusitis: a systematic review. Int Forum Allergy Rhinol. 2019. PMID: 31869863. doi:10.1002/alr.22473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。